Trends in tobacco smoking and bladder and lung-bronchial cancer rates among non-hispanic white Americans (2000-2016)
- PMID: 40275317
- PMCID: PMC12020030
- DOI: 10.1186/s13690-025-01585-5
Trends in tobacco smoking and bladder and lung-bronchial cancer rates among non-hispanic white Americans (2000-2016)
Abstract
Background: Cancer incidence may be linked to cumulative exposure to environmental factors, including diet, lifestyle behaviors, licit drug use (such as tobacco), and endogenous processes. Tobacco smoking (TS) is strongly associated with bladder cancer (BC) and lung-bronchial cancer (LBC). This study aimed to analyze TS, BC, and LBC rates; their correlation with sex and age; and the risk of subsequent primary cancers among BC and LBC patients in non-Hispanic white Americans (NHWAs) from 13 U.S. states.
Methods: The percentage of smokers in 13 U.S. states from 2000 to 2016 was obtained from the Centers for Disease Control and Prevention (CDC) database. LBC and BC cases in NHWAs from 2000 to 2016 were analyzed as single primary cancers or as the first of two or more neoplasms using the United States Surveillance, Epidemiology, and End Results (SEER) database.
Results: The percentage of NHWA smokers decreased in all 13 U.S. states evaluated in this study from 2000 to 2016. Over 17 years, the incidence rates of BC were 36.37 and 11.66 cases per 100,000 among men and women, respectively, while those of LBC were 68.21 and 61.53 cases per 100,000, respectively. The highest incidence rates of BC and LBC occurred in individuals over 64 years of age: BC in New York (208.9 per 100,000 men) and Massachusetts (54.33 per 100,000 women), and LBC in Kentucky (503.1 per 100,000 men; 298.5 per 100,000 women). The incidence rates of BC and LBC were correlated in most states, especially in Massachusetts, California, New Jersey, and New York. Among the 657,117 patients with LBC, 4.3% had a second type of cancer, while among the 240,461 patients with BC, 14.3% had a second type.
Conclusion: Despite a significant decrease in the number of smokers in the United States between 2000 and 2016, the incidence of BC in men and LBC in women has not followed a similar decline. The odds ratio of a patient diagnosed with primary BC developing a second neoplasm is 3.3 times greater than that of a patient diagnosed with primary LBC.
Keywords: Bladder cancer; Bronchial cancer; Lung cancer; Smoking.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: We report a retrospective study of archived and fully anonymized data from the SEER and CDC databases. We followed all the required steps for the data release policy and data user agreement of the SEER and CDC. This project was evaluated and approved by the Príncipe Ethics Committee of Pequeno Principe College, Curitiba, Paraná, Brazil, and informed consent was waived. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Figures





Similar articles
-
Surveillance for cancers associated with tobacco use--United States, 1999-2004.MMWR Surveill Summ. 2008 Sep 5;57(8):1-33. MMWR Surveill Summ. 2008. PMID: 18772853
-
Surveillance for Cancers Associated with Tobacco Use - United States, 2010-2014.MMWR Surveill Summ. 2018 Nov 2;67(12):1-42. doi: 10.15585/mmwr.ss6712a1. MMWR Surveill Summ. 2018. PMID: 30383737 Free PMC article.
-
Assisted reproductive technology surveillance--United States, 2011.MMWR Surveill Summ. 2014 Nov 21;63(10):1-28. MMWR Surveill Summ. 2014. PMID: 25412164
-
Epidemiology, Screening, and Prevention of Bladder Cancer.Eur Urol Oncol. 2022 Dec;5(6):628-639. doi: 10.1016/j.euo.2022.10.003. Epub 2022 Nov 1. Eur Urol Oncol. 2022. PMID: 36333236 Review.
-
Cancer of the Larynx-20-Year Comparative Survival and Mortality Analysis by Age, Sex, Race, Stage, Grade, Cohort Entry Time-Period, Disease Duration and ICD-O-3 Topographic Primary Sites-Codes C32.0-9: A Systematic Review of 43,103 Cases for Diagnosis Years 1975-2017: (NCI SEER*Stat 8.3.9).J Insur Med. 2024 Jul 1;51(2):92-110. doi: 10.17849/insm-51-2-92-110.1. J Insur Med. 2024. PMID: 39266004
References
-
- Wild CP. Complementing the genome with an exposome: the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev. 2005;14:1847–50. 10.1158/1055-9965.EPI-05-0456 - PubMed
-
- Vineis P, Barouki R. The exposome as the science of social-to-biological transitions. Environ Int. 2022;165:107312. 10.1016/j.envint.2022.107312 - PubMed
LinkOut - more resources
Full Text Sources